BMY - Bristol-Myers Squibb Company
| Previous close | 45.80 |
| Open | 46.05 |
| Bid | 45.48 x 3200 |
| Ask | 45.60 x 4000 |
| Day's range | 45.03 - 46.13 |
| 52-week range | 44.30 - 63.69 |
| Volume | 23,488,951 |
| Avg. volume | 18,850,864 |
| Market cap | 74.378B |
| Beta (3Y monthly) | 0.87 |
| PE ratio (TTM) | 15.12 |
| EPS (TTM) | 3.01 |
| Earnings date | 25 Apr 2019 |
| Forward dividend & yield | 1.64 (3.44%) |
| Ex-dividend date | 2019-04-04 |
| 1y target est | 57.80 |
- Motley Fool•6 hours ago
How Marijuana Legalization Affected OrganiGram and Aphria's Latest Results
These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
- Motley Fool•15 hours ago
3 Cancer Treatment Stocks to Buy in April
These three cancer stocks have tremendous upside potential.
- Motley Fool•yesterday
5 Top Healthcare Stocks to Buy in 2019
Healthcare is hot, and these top healthcare stocks could be among the hottest of them all this year.
- Zacks•2 days ago
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•4 days ago
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
- Zacks•4 days ago
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
Key highlights of the past week are collaborations and pipeline updates.
- Zacks•4 days ago
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.
- Motley Fool•5 days ago
Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
- Zacks•5 days ago
Bristol-Myers' Shareholders Vote for Celgene Acquisition
Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
- Zacks•6 days ago
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
- CNBC•8 days ago
Bristol-Myers shareholders approve drugmaker's $74 billion deal with Celgene
The deal, announced in January, was a hard sell to Bristol shareholders from the start. The approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.
- Business Wire•8 days ago
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
Bristol-Myers Squibb Company (BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG) at the Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their support for this combination,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines.
- Zacks•8 days ago
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
- Financial Times•9 days ago
Bristol-Myers shareholders approve $90bn Celgene takeover
Celgene shareholders also gave their support for the deal, which is expected to close in the third quarter but awaits US regulatory approval. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines,” Bristol-Myers chairman and chief executive Giovanni Caforio said in a statement.
- Zacks•10 days ago
Seattle Genetics' Adcetris Progresses Well Amid Competition
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
- Business Wire•10 days ago
Bristol-Myers Squibb Receives 2019 ENERGY STAR® Partner of the Year – Sustained Excellence Award
The U.S. Environmental Protection Agency (EPA) has recognized Bristol-Myers Squibb Company (BMY) with an ENERGY STAR® Partner of the Year Sustained Excellence Award for its outstanding contributions and leadership to improve the energy efficiency of facilities worldwide. Bristol-Myers Squibb has earned the ENERGY STAR® Partner of the Year award for the past five consecutive years. “We are proud to have our commitment to environmental responsibility recognized with the ENERGY STAR Partner of the Year Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, Bristol-Myers Squibb.
- Barrons.com•11 days ago
Bristol-Myers Squibb, JPMorgan Chase, and Other Dividend-Paying Stocks That Could Beat the Market
Columbia fund manager David King also likes a group of convertible preferred-stock issues, which offer higher yields than common shares.
- Financial Times•11 days ago
Starboard eclipses Elliott as most prolific activist hedge fund
Jeff Smith’s Starboard Value wrestled the crown from Elliott to become the most prolific activist investor in the first quarter of 2019, with new campaigns for a strategic rethink at companies as diverse as drugmaker Bristol-Myers Squibb, ecommerce business eBay and pizza chain Papa John’s. Starboard’s seven new campaigns eclipsed the four launched by Paul Singer’s Elliott Management, which was the most prolific for the previous seven consecutive quarters, and for 10 of the 11 previous quarters, according to data compiled by the boutique investment bank Lazard. Elliott still manages significantly more money — it has assets under management of more than $35bn, compared to Starboard’s $5.5bn, according to regulatory filings — but Starboard has been bolstering its reputation as a formidable opponent for companies it says are not being run to the maximum value for shareholders.
- Zacks•11 days ago
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
Bristol-Myers Squibb (BMY) closed the most recent trading day at $45.98, moving -1.73% from the previous trading session.
- Zacks•12 days ago
Celgene & Acceleron Submit BLA for Luspatercept to the FDA
Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.
- Zacks•13 days ago
Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY)
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks•15 days ago
Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
Exelixis (EXEL) performance has been impressive so far in 2019 on the back of label expansion of Cabometyx.
- Zacks•16 days ago
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
- Zacks•16 days ago
Health Day Checkup of Medical ETFs: 5 Top Picks
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
